688247 宣泰医药
2025/09 - 九个月2024/122023/122022/122021/12

盈利能力分析
净资产收益率 ROE (%)4.91810.2855.1169.87321.287
总资产报酬率 ROA (%)4.3629.0734.5348.45616.816
投入资产回报率 ROIC (%)4.7999.9524.8909.30919.005

边际利润分析
销售毛利率 (%)40.81451.63155.89371.22978.127
营业利润率 (%)20.98828.12323.01440.04338.455
息税前利润/营业总收入 (%)20.39126.53419.59235.94248.129
净利润/营业总收入 (%)19.14624.96020.36737.53942.767

收益指标分析
经营活动净收益/利润总额(%)79.28689.80481.64765.80162.767
价值变动净收益/利润总额(%)13.2508.47717.22822.3443.111
营业外收支净额/利润总额(%)-0.391-1.266-4.578-1.69918.589

偿债能力分析
流动比率 (X)12.2139.46210.49410.5916.913
速动比率 (X)11.0818.4699.56210.2646.461
资产负债率 (%)10.18612.40611.11611.63818.551
带息债务/全部投入资本 (%)-2.828-3.390-0.826-0.377-2.280
股东权益/带息债务 (%)-3,455.305-2,875.378-11,620.942-25,208.639-4,074.718
股东权益/负债合计 (%)881.741706.049799.583759.286439.047
利息保障倍数 (X)-39.528-21.447-8.114-10.47253.844

营运能力分析
应收账款周转天数 (天)76.16159.61578.16776.12038.113
存货周转天数 (天)132.526136.038155.124176.402214.523